Spirometry: Performance and Interpretation. A Guide for General Practitioners



Similar documents
PULMONARY FUNCTION TESTS A Workshop on Simple Spirometry & Flow Volume Loops

SPIROMETRY FOR HEALTH CARE PROVIDERS Global Initiative for Chronic Obstructive Lung Disease (GOLD)

Forced vital capacity: maximal volume of air exhaled with maximally forced effort from a maximal inspiration.

Spirometry Workshop for Primary Care Nurse Practitioners

Tests. Pulmonary Functions

SPIROMETRY IN PRACTICE

Interpretation of Pulmonary Function Tests

A Guide to Performing Quality Assured Diagnostic Spirometry

THE EUROPEAN COMMUNITY RESPIRATORY HEALTH SURVEY II ECRHS II LUNG FUNCTION PROTOCOL, DATA SHEETS AND LUNG FUNCTION QUESTIONNAIRE

Chronic obstructive pulmonary disease (COPD)

COPD. Information brochure for chronic obstructive pulmonary disease.

Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD)

COVER PAGE FOR the PDF file of PULMONARY FUNCTION TESTING

Pathway for Diagnosing COPD

COPD Prescribing Guidelines

Understanding Pulmonary Function Testing. PFTs, Blood Gases and Oximetry Skinny Little Reference Guide

Spirometry Testing in Occupational Health Programs. Best Practices for Healthcare Professionals

COPD and Asthma Differential Diagnosis

Spirodoc. One Touch Laboratory for respiratory analysis two functional modes: doctor and patient. Spirometer with Touch Screen display

COPD PROTOCOL CELLO. Leiden

GCE AS/A level 1661/01A APPLIED SCIENCE UNIT 1. Pre-release Article for Examination in January 2010 JD*(A A)

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children

ASTHMA IN INFANTS AND YOUNG CHILDREN

National Learning Objectives for COPD Educators

Understanding COPD. Carolinas Healthcare System

Your Go-to COPD Guide

RESPIRATORY VENTILATION Page 1

1 ALPHA-1. What is Alpha-1? A family history... of lung disease? of liver disease? FOUNDATION

WAY OF WORKING LUNG PATIENTS

PLAN OF ACTION FOR. Physician Name Signature License Date

Better Breathing with COPD

Pulmonary Disorders. Chronic Obstructive Pulmonary Disease (COPD) Chronic Obstructive Pulmonary Disease (COPD)

An Overview of Asthma - Diagnosis and Treatment

These factors increase your chance of developing emphysema. Tell your doctor if you have any of these risk factors:

COPD. What is COPD? How many people have COPD in Canada? Who gets COPD?

Pet/Enright_v34 1/30/07 4:14 PM Page 2

The patient s response to therapy within the first hour in the Emergency Room is one of the most reliable ways to predict need for hospitalization.

FIBROGENIC DUST EXPOSURE

written by Harvard Medical School COPD It Can Take Your Breath Away

Defending the Rest Basics on Lung Cancer, Other Cancers and Asbestosis: Review of the B-Read and Pulmonary Function Testing

Emphysema. Introduction Emphysema is a type of chronic obstructive pulmonary disease, or COPD. COPD affects about 64 million people worldwide.

COPD It Can Take Your Breath Away

Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age

Spirometry, the most frequently performed

COURSE SYLLABUS RC 223 CLINICAL-3

Standardisation of spirometry

Department of Surgery

Pre-Operative Services Teaching Rounds 2 Jan 2011

Spirodoc. 3D Laboratory for respiratory analysis two functional modes: doctor and patient. Four devices in one. Spirometer with Touch Screen display

Lothian Guideline for Domiciliary Oxygen Therapy Service for COPD

British Guideline on the Management of Asthma

MILITARY (ACTIVE DUTY)-SPECIFIC ISSUES

Sponsor Novartis Pharmaceuticals

medicineupdate to find out more about this medicine

Virginia Tech Departmental Policy 27 Sports Medicine Key Function:

Breathing Easier In Tennessee: Employers Mitigate Health and Economic Costs of Chronic Obstructive Pulmonary Disease

Pharmacology of the Respiratory Tract: COPD and Steroids

GRADE 11F: Biology 3. UNIT 11FB.3 9 hours. Human gas exchange system and health. Resources. About this unit. Previous learning.

microlife PF 100 Electronic Asthma Monitor Instruction Manual (1-15) Moniteur d'asthme électronique Mode d'emploi (16-31) Monitor electrónico para el

Coding Guidelines for Certain Respiratory Care Services July 2014

Restrictive vs. Obstructive Disease (Dedicated to my good friend Joe Walsh)

Airways Resistance and Airflow through the Tracheobronchial Tree

Insights for Improvement: Advancing COPD Care Through Quality Measurement. An NCQA Insights for Improvement Publication

Call Your Home Health Nurse and/or Physician. Call 911. Self Management for COPD COMMUNITY HEALTH AND COUNSELING SERVICES

RES/006/APR16/AR. Speaker : Dr. Pither Sandy Tulak SpP

Asthma. Micah Long, MD

Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD)

1 ALPHA-1. Am I an Alpha-1 Carrier? FOUNDATION FOUNDATION. Learn how being an Alpha-1 carrier can affect you and your family

Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma

MicroLab. Operating Manual

Abnormalities Consistent with Asbestos-Related Disease Among Long-Term Demolition Workers

Lab #11: Respiratory Physiology

Pulmonary Diseases. Lung Disease: Pathophysiology, Medical and Exercise Programming. Overview of Pathophysiology

Chronic Obstructive Pulmonary Disease Patient Guidebook

Irish Association for Emergency Medicine (IAEM) submission to the National COPD Strategy

Pulmonary Rehabilitation in Newark and Sherwood

Oxygenation. Chapter 21. Anatomy and Physiology of Breathing. Anatomy and Physiology of Breathing*

Vmax Vyntus SPIRO. Advance your lung function testing experience

Management of exacerbations in chronic obstructive pulmonary disease in Primary Care

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Things you might want to ask about asthma

WHEN COPD* SYMPTOMS GET WORSE

Salamol CFC-Free Inhaler

Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD)

Oxygen Therapy. Oxygen therapy quick guide V3 July 2012.

Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD)

Twenty years of innovative solutions in Spirometry, Oximetry, Telemedicine

Asthma Intervention. An Independent Licensee of the Blue Cross and Blue Shield Association.

Understanding Hypoventilation and Its Treatment by Susan Agrawal

COPD - Education for Patients and Carers Integrated Care Pathway

Managing Asthma Long Term

2.06 Understand the functions and disorders of the respiratory system

Objectives COPD. Chronic Obstructive Pulmonary Disease (COPD) 4/19/2011

Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis, and asthma

Childhood Asthma / Wheeze

5. Treatment of Asthma in Children

Pulmonary Rehab FAQ s (Abstracted from AACVPR site)

Drug therapy SHORT-ACTING BETA AGONISTS SHORT-ACTING ANTICHOLINERGICS LONG-ACTING BETA AGONISTS LONG-ACTING ANTICHOLINERGICS

Pulmonary Function Testing: Coding and Billing Issues

Clinical guideline Published: 23 June 2010 nice.org.uk/guidance/cg101

Transcription:

Irish Thoracic Society Spirometry: Performance and Interpretation A Guide for General Practitioners Dr. Terry O Connor, Consultant Respiratory Physician, Mercy University Hospital, Cork Dr. Pat Manning, Consultant Respiratory Physician, Bon Secours Hospital, Dublin 9 November 2005 http://www.irishthoracicsociety.com

CONTENTS Page 1. Spirometry 2 2. Spirometry curves 3 3. Which spirometer? 4 4. Performing the test 5 5. Maintaining accuracy of the test 7 6. Identifying errors in spirometry traces 8 7. Interpreting the results 9 8. Spirometry Diagnostic Flowchart 11 9. Assessing the flow volume curve 13 10. Changes in FEV 1 due to aging and the detrimental effects of smoking 14 1

1. Spirometry Peak flow meters, whilst useful for monitoring obstruction in asthma and COPD from day to day, are of little value in diagnosing these diseases as the readings may lead to a serious underestimate of the extent of airway impairment. Spirometry measures the volume of air that the patient is able to expel from the lungs after maximal inspiration. Spirometry is invaluable as a screening test of general respiratory health, similar to BP measurement in cardiovascular disease. It is a reliable method of diagnosing and differentiating between obstructive airways disorders (e.g. COPD, asthma) and restrictive diseases (where the size of the lung is reduced, e.g. fibrotic lung disease). Spirometry can also be used to determine the severity of asthma and COPD. This is important because the severity of these diseases cannot be predicted simply from the clinical signs and symptoms. The FEV 1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration (expressed in litres at BTPS). The forced vital capacity (FVC) is the maximal volume of air exhaled with maximally forced effort from a maximal inspiration (expressed in litres at body temperature and ambient pressure saturated with water vapour BTPS). Some indicators that suggest spirometry may be warranted include: To screen individuals at risk for pulmonary disease e.g. smokers To evaluate patients with chronic, progressive symptoms of cough, wheeze and breathlessness Frequent exacerbations of bronchitis Patients whose occupations may expose them to respiratory irritants (fumes and dusts) To assess pre-operative risks Family history of pulmonary disease (eg. α 1-antitrypsin deficiency) As part of insurance evaluation The Irish Thoracic Society recommends the use of spirometry to confirm diagnosis and assess response to treatment in asthma and COPD. Most patients with COPD do not present clinically until they have moderate or severe level of disease. One of the most important advantages of spirometry is that enables one to detect COPD before the symptoms become apparent. Early identification and persuading patients to stop smoking may mean minimal disease progression and long-term improved quality of life. 2

2. Spirometry curves The Time-Volume curve The Flow volume curve 3

3. Which Spirometer? There are many different devices available: volume-displacement devices (piston, bellows or water sealed bell) or flow sensing (measuring pressure drop across resistance, turbine rotation or the cooling of a heated wire). Ideally, a spirometer should have a graphical display to allow technical errors to be detected. It should be able to produce a hard copy. Regular calibration is essential. Three types of spirometer are commonly used in primary care: Small, hand held meters which provide digital readings. These are the cheapest option and small enough to fit into a medical bag and produce FEV 1 and FVC readings. The lack of graphs can make it difficult to judge when a blow is complete. Predicted charts and a calculator will be needed to interpret the results. Portable meters with integral printers. More advanced spirometers produce traces (i.e. visual display or print-out) of the volume of air exhaled over time so you can see how well the patient has carried out the maneuver. These are more expensive but they will undertake all the calculations, including reversibility. Small displays of the volume time graph help monitor the blow and the printout includes a flow volume loop. If your spirometry has a memory facility, you may also store the trace. Systems designed to work with a computer Many electronic spirometers also display a flow-volume curve. You do not need this information to calculate FEV 1 and FVC values for your patient, so it is not necessary to use this facility when you are beginning. These systems display a graph, calculate predicted and reversibility and provide a printout. Your local pulmonary function laboratory may be able to recommend a specific device. 4

4. Performing the test 1. Explain the purpose and method of the test to the patient (correct posture with head slightly elevated). The test involves maximal rapid inspiration, followed by forced exhalation of air through the mouthpiece sealed by mouth. It is useful to demonstrate the correct technique to the patient and ask the patient to undertake practice attempts beforehand. 2. Prepare the patient (ask about smoking, recent illness, medication use and measure weight, height and age). 3. Input the patient data where appropriate. 4. Attach a clean, disposable mouthpiece to the spirometer (a fresh one for each patient). 5. Ensure that the patient is comfortable, in particular that they are seated (in case they experience any faintness during the procedure). Attach a clean nose clip, place mouthpiece in the mouth and close lips around this. Inhale completely and rapidly with a pause of no longer than < 1 sec at full inspiration. Then exhale maximally until no more air can be expelled while maintaining an upright posture. a. Encourage the patient to keeping blowing out. Ensure that patient has exhaled for at least 6 seconds; the blow should continue until a volume plateau is reached. For patients with severe COPD this can take up to 15 seconds. b. Some spirometers give a bleep to confirm the maneuver is complete. c. Actively encourage patient as they perform the test i. Take a deep breath in and fill up your lungs ii. Now BLAST IT OUT as hard as you can and KEEP BLOWING, KEEP BLOWING, KEEP BLOWING d. Watch the patient during the procedure to ensure maximal effort e. Assess the flow volume curve for evidence of poor effort, hesitation etc. 6. Now repeat the procedure, and then repeat it again (but no more than 8 times as patients will fatigue). You should have three readings of which at least two of the FVC and FEV 1 components are reproducible, i.e. within 100ml, or 5%, of each other. The expiratory volume-time graph should be smooth and free from irregularities. 5

7. Depending on your model of spirometer the results may appear on a display (which you may be able to store against the date and time) or may be printed. 8. If spirometry shows airflow obstruction or you suspect a diagnosis of asthma, consider proceeding with reversibility testing.. a. Reversibility tests involves performing spirometry before and after bronchodilator therapy and can help distinguish between asthma and COPD (note that spirometry may be normal in stable asthma). b. The patient's condition should be stable (i.e. at least 6 weeks since an exacerbation). Before a bronchodilator reversibility test, the patient should stop their short acting 2 agonist for 6 hours, long acting bronchodilator for 12 hours and theophyllines for 24 hours. Avoid smoking for 1 hour prior to and during the test. 9. Perform baseline spirometry. Administer bronchodilator (at least 400mcg salbutamol or bricanyl, e.g. 4 puffs using a spacer device e.g. volumatic spacer or 5mg by nebuliser). Then perform spirometry again after 15 minutes. An increase in FEV 1 of >12% and >200mls suggests significant reversible airflow obstruction). 10. A steroid trial (30-40mg prednisolone daily for 2 weeks or 1,000 g of inhaled corticosteroid for three months) may also be appropriate to assess bronchodilator reversibility if asthma is still suspected. 6

5. Maintaining accuracy of the test The most common reason for inconsistent readings is patient technique. Errors may be detected by observing the patient throughout the manoeuvre and by examining the trace. Common problems include: Lips not tight around the mouthpiece Inadequate or incomplete inhalation A slow start to the forced exhalation Exhalation stops before complete expiration Some exhalation through the nose Additional breath taken during maneuver Coughing N.B. Spirometers should be kept clean, and accuracy checked regularly in accordance with the manufacturer s recommendations. 7

6. Identifying errors in spirometry traces Hesitation Premature finish Cough Poor effort Premature finish and restart 8

7. Interpreting the results 1. Start with the FEV 1/FVC ratio 2. In airflow obstruction, patients cannot exhale the air in their lungs quickly. Therefore, the FEV 1 tends to fall, while the FVC remains relatively preserved (falling only in more severe airflow obstruction). The FEV 1/FVC ratio is reduced below 70%. If this is the case, the patient may have asthma, COPD or another cause of airflow obstruction proceed to point 5 3. If the FEV 1/FVC ratio is greater than 70%, this usually represents normal pulmonary function but can occasionally represent restrictive disease. If the absolute values of FEV 1 and FVC are normal, then the test is normal. If the FEV 1 and FVC values are proportionately reduced, then the patient may have restrictive pulmonary disease. 4. The commonest cause of apparent restrictive disease is poor technique, where the apparent reduction in FEV 1 and FVC are due to poor patient effort rather than a true reduction in their value this underscores the importance of observation of patient effort during the procedure. 5. The degree of airflow obstruction allows a classification of disease severity using the GINA (asthma) or GOLD (COPD) guidelines, and appropriate choice of therapy or action. 6. Assess the flow-volume curve to confirm your impression of the diagnosis (see below). 7. In a patient with respiratory symptoms, airway obstruction where the FEV 1 increases by 12% and 200 mls following bronchodilator therapy is suggestive of asthma. 8. In a patient with intermittent respiratory symptoms, the lack of airway obstruction, or the lack of a bronchodilator response do not rule out asthma. Similarly, a bronchodilator response with normal spirometry does not always indicate asthma. 9. Airway obstruction in an adult smoker is usually (but not always) due to COPD. 10. After spirometry, if you remain uncertain of the diagnosis, consider referral to a hospital pulmonary function laboratory for lung volumes and a diffusing capacity estimation (to assess for evidence of emphysema or 9

interstitial lung disease) or a histamine or methacholine inhalation challenge test or exercise test (to evaluate for asthma). Obstructive Restrictive Combined FEV 1/FVC% N or FVC N or FEV 1 N or N Normal - Increased compared to predicted value - Decreased compared to predicted value 10

8. Spirometry Diagnostic Flowchart 11

* Reversibility testing with -agonist indicates an improvement of > 12% and >200ml in FEV 1 and/or FVC approximately 15 mins after inhalation. ** Full PFT S refers to the measurement of diffusing capacity DL CO and lung volumes using dilution or plethysmographic techniques in a computerized hospital based respiratory function laboratory to determine the severity of the defect. *** Some subjects with chronic asthma may not respond at all to a -agonist. Some COPD patients may show an improvement post -agonist. 12

9. Assessing the flow volume curve Airflow Obstruction Normal Mild Airflow Obstruction Moderate Airflow Obstruction Severe Airflow Obstruction Restrictive Disease Normal Moderate Restrictive Defect Severe Restrictive Defect 13

10. Changes in FEV 1 due to aging and the detrimental effects of smoking 14